Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E8KO
|
|||
| Former ID |
DIB011217
|
|||
| Drug Name |
Anti-CD3 activated vaccine-primed lymphocytes
|
|||
| Synonyms |
VPLN tumor vaccine, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer); Monoclonal antiobody activated vaccine-primed lymphocytes (cancer), University of Michigan; Vaccine-primed lymph node (VPLN) cells, University of Michigan; Anti-CD3 activated vaccine-primed lymphocytes (cancer), University of Michigan; Anti-CD3/anti-CD28 activated vaccine-primed lymphocytes (cancer), University of Michigan
Click to Show/Hide
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Company |
University of Michigan
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003 Mar 1;21(5):884-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.